GlassScriptPhysician profile
Kerri Bally
NPI 1245606805
$2,419.85
in general payments reported to CMS, 2019-2025
17 companies · $974 in 2025
The $974 reported for 2025 was more than what 77% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $397 · 2024: $863 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.80 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,010.96 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $384.31 | 2022-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $253.57 | 2024-2025 | |
| Amgen INC. | $181.24 | 2023-2025 | Tezspire |
| Insmed, INC. | $126.30 | 2023-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $114.12 | 2024-2025 | Dupixent |
| Philips North America LLC | $64.47 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Mylan Specialty L.P. | $56.54 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $34.67 | 2024 | Glassia |
| Vifor Pharma, INC. | $33.64 | 2025 | Zemaira |
| Harmony Biosciences LLC | $31.42 | 2024 | |
| Verona Pharma, INC. | $25.71 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $25.53 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.97 | 2024 | |
| United Therapeutics Corporation | $20.65 | 2025 | Tyvaso |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $18.26 | 2025 | Smartvest |
| Paratek Pharmaceuticals, INC. | $16.49 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Bally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.